Detalhe da pesquisa
1.
Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac.
Vaccines (Basel)
; 11(2)2023 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36851234
2.
Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine.
Vaccines (Basel)
; 10(10)2022 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36298478
3.
Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment.
Vaccines (Basel)
; 10(10)2022 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36298528
4.
Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls.
Hum Vaccin Immunother
; 18(6): 2094149, 2022 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35776836